Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.

Gilead Sciences has consistently increased its dividend for the past 11 years, reaching a payout ratio of just 29.8%. This indicates a strong financial position to maintain the dividend and fund other operations. The company's HIV treatments, a cornerstone of its business, have been performing well, with an 18% year-over-year increase in sales and nearly doubling of HIV prevention therapy sales.

Gilead's free cash flow has also surged, up 68% year-over-year, reaching $10.6 billion over the past nine months. The company is diversifying its portfolio with investments in oncology and anti-inflammatory treatments, recently opening a research center and planning $32 billion in projects through 2030. Gilead's recent approval of Trodelvy, a drug for bladder and breast cancer, has further boosted its revenue, with sales up 42% year-over-year.

With its oncology and immunology drug pipeline, including emvistegrast, showing promising results, Gilead appears well-positioned to continue its dividend growth streak.